Inventor · disambiguated record
Iraj Hosseini
Also filed as: HOSSEINI IRAJ
4 granted patents·8 pending applications·9 citations·filing 2017–2025
66Inventor score
Files withGENENTECH INC12
Top patents by PatentIndex Score
12 records- 0183US11466094B2Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodiesGENENTECH INC·Filed 2017·Granted Oct 11, 2022·8 cites·82 claims
- 0281US2024376223A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2024·Application pending·0 cites
- 0380US11542308B2FLT3 ligand fusion proteins and methods of useGENENTECH INC·Filed 2022·Granted Jan 3, 2023·1 cites·26 claims
- 0479US2024132613A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2023·Application pending·0 cites
- 0576US2023242659A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2023·Application pending·0 cites
- 0670US2025171552A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2025·Application pending·0 cites
- 0767US2024331829A1Quantitative systems pharmacology in cytokine-based cancer immunotherapyGENENTECH INC·Filed 2024·Application pending·0 cites
- 0864US12240910B2Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of useGENENTECH INC·Filed 2022·Granted Mar 4, 2025·0 cites·47 claims
- 0961US2025239372A1T Cell Quantitative Systems Pharmacology ModelGENENTECH INC·Filed 2025·Application pending·0 cites
- 1051US12492261B2Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodiesGENENTECH INC·Filed 2021·Granted Dec 9, 2025·0 cites·42 claims
- 1151US2025250347A1Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of useGENENTECH INC·Filed 2025·Application pending·0 cites
- 1238US2025297019A1Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodiesGENENTECH INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Iraj Hosseini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →